Clinical trials
Secondary Myelofibrosis clinical trials
Below are recruiting secondary myelofibrosis clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04370301RecruitingPhase 2
Reduced-intensity stem cell transplant with JAK inhibitor for myelofibrosis
This study tests giving a JAK inhibitor before and after a reduced-intensity stem cell transplant to treat primary or secondary myelofibrosis. The goal is to improve disease control while using a less harsh transplant approach.
Seattle, WashingtonAges 18–70 - NCT06516406Recruiting
Ruxolitinib study for primary and secondary myelofibrosis
This study follows patients with myelofibrosis (a type of bone marrow cancer) who are already taking or have taken ruxolitinib. Researchers will review medical records to understand how well the medicine works in everyday practice.
Cosenza, CalabriaAges 18 years+ - NCT07362225Recruiting
MPN Progress Registry: Tracking Symptoms and Progression
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
Chicago, IllinoisAges 18 years+ - NCT06976918Recruiting
Myelofibrosis and Anemia Research Study
This study follows people with myelofibrosis and anemia who are starting a new treatment. It aims to learn more about the disease and how treatments work in real life.
Multiple LocationsAges 18 years+ - NCT07250646RecruitingPhase 1
Rebecsinib for secondary AML or high-risk myelofibrosis
This trial tests a new drug called rebecsinib for people with a certain type of leukemia (secondary acute myeloid leukemia) or a high-risk bone marrow disorder (myelofibrosis) that has come back or not responded to other treatments. The goal is to see if it works and is safe.
Duarte, CaliforniaAges 18 years+ - NCT07228624RecruitingPhase 2
Ruxolitinib before, during, and after transplant for myelofibrosis
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
Seattle, WashingtonAges 18–75 - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Irvine, CaliforniaAges 18 years+ - NCT04282187RecruitingPhase 2
Decitabine plus targeted drugs for advanced blood cancer blast phase
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
Seattle, WashingtonAges 18 years+ - NCT06397313RecruitingPhase 2
New drug for myelofibrosis after JAK inhibitor failure
This trial tests a new drug called RVU120 for people with myelofibrosis that has not responded well to standard JAK inhibitor treatment. It aims to shrink the spleen and improve symptoms.
BolognaAges 18 years+ - NCT05326919Recruiting
Study biobank for people newly diagnosed with certain blood cancers
This study follows people who are newly diagnosed (and haven’t been fully treated yet) with specific leukemia or related blood disorders to help researchers learn which treatments may work best. It may help by connecting you to a larger “precision medicine” patient group for future research.
BobignyAges Any age - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+
Hear when a new Secondary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Secondary Myelofibrosis trials by city
Studies with a site in or near these metro areas.
Secondary Myelofibrosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for secondary myelofibrosis?
- Yes. Clin2 currently lists 11 recruiting secondary myelofibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a secondary myelofibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a secondary myelofibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.